Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Advances in Functional Proteomics Spell Speedier Drug Discovery - Frost & Sullivan finds that the study Functional Proteomics provides market drivers, technical challenges, and emerging enabling technologies in this space
Advances in Functional Proteomics Spell Speedier Drug Discovery

 

PRZOOM - /newswire/ - Palo Alto, CA, United States, 2007/09/13 - Frost & Sullivan finds that the study Functional Proteomics provides market drivers, technical challenges, and emerging enabling technologies in this space.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Proteomics research is undergoing excessive growth. Nearly every major biotech and pharmaceuticals firm has implemented a proteomics program. Functional proteomics, the study of protein function and identification of protein interactions, is playing a major role in drug discovery, biomarkers, molecular diagnostics, and antibody therapies. A primary goal of biomedical research is discovering how cells respond to genetic instructions by creating thousands of protein variations and observing their reactions.

Frost & Sullivan (ti.frost.com) finds that the study Functional Proteomics provides market drivers, technical challenges, and emerging enabling technologies in this space. It also describes a variety of results obtained using these technologies.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of the latest analysis of the Functional Proteomics, then send an email to Melina Trevino - Corporate Communications at melina.trevino[.]frost.com with the following information: your full name, company name, title, telephone number, email address, city, state, and country. We will send you the information via email upon receipt of the above information.

"Functional proteomics is developing at a rapid pace to address a critical need in the discovery of drug targets, with the development of a single drug costing an average of $500 million, and only 30 percent of approved drugs recovering these costs," says Frost & Sullivan Research Analyst Katherine Austin. "To address this need, pharmaceuticals companies need to find out methods to collect large amounts of data to dissect the complex, disease-causing interactions between proteins within the cell, and between proteins in the extra-cellular environment."

Functional proteomic technologies enable identification of functions for uncharacterized human proteins, the discovery of other proteins with which they interact, and an understanding of their involvement in important disease pathways. Understanding cell-signaling pathways and the manner in which cells communicate will provide greater understanding of disease mechanisms, revealing potential drug targets that are more likely to succeed. After the development of drugs, pathway knowledge is critical in understanding the downstream effects of drug treatment. Enhanced knowledge of pathways will reduce side affects.

Unfortunately, proteins are far more complicated than DNA. Technical problems have plagued functional proteomic R&D on every front. Problems associated with functional proteomic technologies, such as protein arrays are also numerous.

"The development of various proteomic kits and targeted solutions is fraught with pitfalls, many of which deal with the vast range of chemical and physical properties of different proteins," explains Austin. "Some of these include the complexity of the protein-interaction map, a lack of standardization, which makes it difficult to compare or validate results from different laboratories, and a lack of protein-specific capture agents such as antibodies."

Before accepting functional proteomics as a standard, high throughput approach, technology developers need to address a number of challenges. There is a need for new tools and research strategies on all fronts, for protein expression, purification, screening, and measuring protein interactions. In addition, assay sensitivity– the ability to detect low-abundance proteins–need to be more, by following standard techniques that provide reliable and acceptable results for pharmaceuticals applications.

Functional Proteomics is part of the Technical Insights, Healthcare, and examines the following applications: drug discovery, biomarkers, molecular diagnostics and antibody therapies, enabling technologies: spectometry, microarrays, electrophoresis, immunohistochemistry, yeast and viral expression and identification, affinity chromatography, and immunohistochemistry. Interviews are available to the press.

Technical Insights is an international technology analysis business that produces a variety of technical news alerts, newsletters, and research services.

About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective, and combines ongoing analysis of markets, technologies, econometrics, and demographics.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Advances in Functional Proteomics Spell Speedier Drug Discovery

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Frost & Sullivan |
Contact: Melina Trevino 
210.247.2440 melina.trevino[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona

Visit  NAKIVO, Inc.







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today